Patents Examined by Kahsay Habte
  • Patent number: 12291524
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: May 6, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Daniel Tor Pettersen, Stéphanie Marcelle Gueret, Nidhal Selmi, Erik Lars Malmerberg, Tord Bertil Inghardt, Jan Åke Lindberg, Jens Peter Brandt, Jon Paul Janet, Björn Erik Anton Holm
  • Patent number: 12287338
    Abstract: Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating gene levels of the biomarkers and methods of using such gene levels to predict a cancer patient's response to the MDM2 inhibitors or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor. Such information can be used in determining prognosis and treatment options for cancer patients.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: April 29, 2025
    Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
    Inventors: Yifan Zhai, Dajun Yang, Douglas Dong Fang, Ran Tao
  • Patent number: 12286427
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: July 19, 2024
    Date of Patent: April 29, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Patent number: 12286420
    Abstract: Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: April 29, 2025
    Assignees: OHIO STATE INNOVATION FOUNDATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Kevin Hodgetts, Chien-Liang Glenn Lin
  • Patent number: 12281078
    Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 22, 2025
    Assignees: Immunesensor Therapeutics, Inc., The Board of Regents of The University of Texas System
    Inventors: Qi Wei, Heping Shi, Matt Tschantz, Jian Qiu, Youtong Wu, Huiling Tan, Lijun Sun, Chuo Chen, Zhijian Chen
  • Patent number: 12275746
    Abstract: The present invention relates to pyrrolo[1,2-b]-2-pyridazinone compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as 5-HT4 receptor agonists. The present invention also describes methods of making such compounds, pharmaceutical compositions comprising such compounds, and their use in the treatment of gastrointestinal disease or disorder.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: April 15, 2025
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Vinod Kumar Goyal, Santosh Kumar Pandey, Vijay Sidram Benade, Venkatesh Goura, Venkateswarlu Jasti
  • Patent number: 12275707
    Abstract: Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: April 15, 2025
    Assignee: Escient Pharmaceuticals, Inc.
    Inventors: Marion Lanier, Marcus Boehm, Liming Huang, Esther Martinborough, Marcos Sainz, Brandon Selfridge, Adam Yeager
  • Patent number: 12275716
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: April 15, 2025
    Assignee: Arvinas Operations, Inc.
    Inventors: Andrew P. Crew, Hanqing Dong, Keith R. Hornberger, Yimin Qian, Jing Wang, Craig M. Crews
  • Patent number: 12275717
    Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: April 15, 2025
    Assignee: Ajax Therapeutics, Inc.
    Inventors: Craig E. Masse, Jeremy R. Greenwood, Sayan Mondal, Jiayi Xu, Phani Ghanakota, Fiona Michelle McRobb, Nicholas Boyles
  • Patent number: 12269817
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: April 8, 2025
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito Kakuuchi, Shuhei Umemura, Masaki Asada, Anatoly Ruvinsky, Yan Zhang, Hidenori Takahashi, Goran Krilov, Daigo Inoyama, Kyle Konze, Mats Svensson
  • Patent number: 12264149
    Abstract: Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: April 1, 2025
    Assignee: TYRA BIOSCIENCES, INC.
    Inventors: Robert L. Hudkins, Daniel C. Bensen
  • Patent number: 12264153
    Abstract: The present disclosure provides compounds which are useful for a number of catalytic transformations of organic molecules, non-limiting examples including dehydrogenation of alkanes. The present disclosure further relates to methods of preparing the compounds of the present disclosure.
    Type: Grant
    Filed: April 22, 2024
    Date of Patent: April 1, 2025
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Alan S. Goldman, Thomas R. Dugan
  • Patent number: 12264169
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: April 1, 2025
    Assignee: Tetra Discovery Partners
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Patent number: 12264152
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Grant
    Filed: January 17, 2023
    Date of Patent: April 1, 2025
    Assignee: Algen Biotechnologies, Inc.
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • Patent number: 12264154
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: April 1, 2025
    Assignee: Tango Therapeutics, Inc.
    Inventors: Kevin M. Cottrell, John P. Maxwell
  • Patent number: 12264165
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: April 1, 2025
    Assignee: Kancera AB
    Inventors: Jan Vågberg, Styrbjörn Byström
  • Patent number: 12258338
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: March 25, 2025
    Assignee: Evotec International GmbH
    Inventors: Holly Atton, Christopher John Brown, James Lindsay Carr, Serge Convers-Reignier, Michael Corr, Marissa Flower, Christopher Francis Palmer, Irena Reboule, Mohamad Sabbah, Scott Sadler, Jonathan Shine, Daryl Simon Walter
  • Patent number: 12258423
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: March 25, 2025
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 12239640
    Abstract: The invention discloses use of miloxacin in the preparation of medicines for treating and/or preventing diseases with T-type calcium channel as a therapeutic target. The invention discloses new use of miloxacin, which provides a new theoretical and technical support for developing medicines for treating and/or preventing diseases with T-type calcium channel as a therapeutic target, thus having a broad prospect of application in the field of clinical treatment.
    Type: Grant
    Filed: February 20, 2021
    Date of Patent: March 4, 2025
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Jin Tao, Yuan Zhang, Yufang Sun, Xinghong Jiang
  • Patent number: 12240831
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele